Shenzhen New Industries Biomedical (300832) - Total Liabilities
Based on the latest financial reports, Shenzhen New Industries Biomedical (300832) has total liabilities worth CN¥831.98 Million CNY (≈ $121.74 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shenzhen New Industries Biomedical - Total Liabilities Trend (2012–2024)
This chart illustrates how Shenzhen New Industries Biomedical's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Shenzhen New Industries Biomedical to evaluate short-term liquidity relative to the company's equity base.
Shenzhen New Industries Biomedical Competitors by Total Liabilities
The table below lists competitors of Shenzhen New Industries Biomedical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Salubris Pharmaceuticals Co Ltd
SHE:002294
|
China | CN¥2.05 Billion |
|
Reynolds Consumer Products Inc
NASDAQ:REYN
|
USA | $2.67 Billion |
|
California Resources Corp
NYSE:CRC
|
USA | $4.23 Billion |
|
DEME Group NV
BR:DEME
|
Belgium | €3.78 Billion |
|
Yinyi Real Estate Co Ltd
SHE:000981
|
China | CN¥4.61 Billion |
|
NOVA LJUBLJ.BK GDR REG.S
F:N1V2
|
Germany | €28.31 Billion |
|
Hisense Electric Co Ltd
SHG:600060
|
China | CN¥18.63 Billion |
|
Turk Telekomunikasyon AS
IS:TTKOM
|
Turkey | TL214.22 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Shenzhen New Industries Biomedical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300832 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen New Industries Biomedical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen New Industries Biomedical (2012–2024)
The table below shows the annual total liabilities of Shenzhen New Industries Biomedical from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.04 Billion ≈ $152.60 Million |
+53.79% |
| 2023-12-31 | CN¥678.09 Million ≈ $99.23 Million |
+10.25% |
| 2022-12-31 | CN¥615.06 Million ≈ $90.00 Million |
+17.49% |
| 2021-12-31 | CN¥523.51 Million ≈ $76.61 Million |
+4.39% |
| 2020-12-31 | CN¥501.49 Million ≈ $73.38 Million |
+57.24% |
| 2019-12-31 | CN¥318.92 Million ≈ $46.67 Million |
+16.17% |
| 2018-12-31 | CN¥274.52 Million ≈ $40.17 Million |
+9.81% |
| 2017-12-31 | CN¥250.00 Million ≈ $36.58 Million |
+34.59% |
| 2016-12-31 | CN¥185.75 Million ≈ $27.18 Million |
+48.66% |
| 2015-12-31 | CN¥124.94 Million ≈ $18.28 Million |
-7.39% |
| 2014-12-31 | CN¥134.92 Million ≈ $19.74 Million |
-16.78% |
| 2013-12-31 | CN¥162.12 Million ≈ $23.72 Million |
+149.68% |
| 2012-12-31 | CN¥64.93 Million ≈ $9.50 Million |
-- |
About Shenzhen New Industries Biomedical
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was found… Read more